Canaccord Genuity Reaffirms Buy Rating on Compass Therapeutics

Canaccord Genuity has reaffirmed its Buy rating on Compass Therapeutics (Ticker: CF) after positive results from the Phase 2/3 COMPANION-002 study of tovecimig for advanced biliary tract cancer. The study met its primary and key secondary endpoints, which has influenced Canaccord Genuity's continued support based on the clinical data and the company's development progress.